Literature DB >> 18725443

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

Asunción Fenoll, Lorenzo Aguilar, Olga Robledo, María-José Giménez, Juan-José Granizo, Donald Biek, David Tarragó.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18725443      PMCID： PMC2573151          DOI： 10.1128/AAC.00712-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones.

Authors:  Asunción Fenoll; María-José Giménez; Olga Robledo; Pilar Coronel; Mercedes Gimeno; Julio Casal; Lorenzo Aguilar
Journal:  Int J Antimicrob Agents       Date:  2006-12-18       Impact factor: 5.283

2.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Nosocomial bloodstream infections caused by Streptococcus pneumoniae.

Authors:  E Bouza; V Pintado; S Rivera; R Blázquez; P Muñoz; E Cercenado; E Loza; M Rodríguez-Créixems; S Moreno
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

4.  Hospital-acquired pneumococcal bacteremia.

Authors:  Joan-Josep Canet; Natalia Juan; Mariona Xercavins; Núria Freixas; Javier Garau
Journal:  Clin Infect Dis       Date:  2002-08-26       Impact factor: 9.079

5.  Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae.

Authors:  A Fenoll; M J Giménez; O Robledo; L Aguilar; D Tarragó; J J Granizo; J E Martín-Herrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-18       Impact factor: 3.267

6.  In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

Authors:  Shazad Mushtaq; Marina Warner; Yigong Ge; Koné Kaniga; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2007-06-04       Impact factor: 5.790

7.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Authors:  Yuji Iizawa; Junko Nagai; Tomoyasu Ishikawa; Shohei Hashiguchi; Masafumi Nakao; Akio Miyake; Kenji Okonogi
Journal:  J Infect Chemother       Date:  2004-06       Impact factor: 2.211

Review 8.  Nosocomial pneumonia : rationalizing the approach to empirical therapy.

Authors:  Gunnar I Andriesse; Jan Verhoef
Journal:  Treat Respir Med       Date:  2006
  8 in total
  12 in total

1.  Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008.

Authors:  A Fenoll; L Aguilar; M D Vicioso; M J Gimenez; O Robledo; J J Granizo; C Mendez
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

3.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

5.  Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  K Kosowska-Shick; P L McGhee; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

6.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

7.  Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly E Steed; Céline Vidaillac; Patricia Winterfield; Donald Biek; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 8.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009.

Authors:  Asunción Fenoll; Lorenzo Aguilar; Maria-Dolores Vicioso; Maria-Jose Gimenez; Olga Robledo; Juan-Jose Granizo
Journal:  BMC Infect Dis       Date:  2011-09-12       Impact factor: 3.090

10.  Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.

Authors:  Diego J Maselli; Juan F Fernandez; Christine Y Whong; Kelly Echevarria; Anoop M Nambiar; Antonio Anzueto; Marcos I Restrepo
Journal:  Infect Drug Resist       Date:  2012-02-01       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.